8-K12B: iRhythm Technologies Reorganizes, Boosts 2025 Revenue Outlook

iRhythm Technologies, Inc. announced a corporate reorganization into a holding company structure, provided strong preliminary Q4 2025 results, and issued an optimistic 2026 financial outlook.

Summary

• iRhythm Technologies, Inc. (the 'Company') has implemented a corporate holding company structure, forming iRhythm Holdings, Inc. as the new parent company.
• The original iRhythm Technologies, Inc. will continue as a wholly-owned subsidiary of iRhythm Holdings, Inc.
• The reorganization is intended to be a tax-free transaction for U.S. federal income tax purposes, with existing stockholders automatically converting their shares on a one-for-one basis to iRhythm Holdings Common Stock.
• iRhythm Holdings Common Stock will continue to trade on the Nasdaq Global Select Market under the ticker symbol IRTC with the same CUSIP number (450056106).
• The Nasdaq marketplace will reflect the name change from iRhythm Technologies, Inc. to iRhythm Holdings, Inc. on January 13, 2026.
• The assets, businesses, and operations of iRhythm Holdings on a consolidated basis are not materially different from those of iRhythm Technologies, Inc. prior to the transaction.
• A first supplemental indenture was entered into for the 1.50% Convertible Senior Notes due 2029, changing conversion rights to iRhythm Holdings Common Stock and providing a full and unconditional guarantee by iRhythm Holdings.
• iRhythm Technologies, Inc. will file to deregister its common stock and suspend reporting obligations, with iRhythm Holdings, Inc. becoming the successor issuer for SEC filings.
• Preliminary full year 2025 revenue is anticipated to exceed the high end of the previously stated guidance range of $740 million, driven by record revenue unit volume in Q4 2025.
• For fiscal year 2026, the company expects revenue of approximately $870 million to $880 million, representing 17% to 18% year-over-year growth.
• Adjusted EBITDA margin for fiscal year 2026 is anticipated to be approximately 11.5% to 12.5%.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook with strong preliminary 2025 results, optimistic 2026 guidance, significant operational achievements (FDA remediation, FCF positive), and clear growth strategies (AI, new products, international expansion). The corporate reorganization is presented as a non-material, tax-free event for shareholders, maintaining continuity. The only minor detraction is the inherent risks associated with forward-looking statements, which are standard.

Positives

• Anticipate full year 2025 revenue to exceed the high end of previously stated guidance of $740 million, driven by record Q4 2025 unit volume.
• Expect strong revenue growth for full year 2026, with estimates of $870 million to $880 million, representing 17% to 18% year-over-year growth.
• Anticipate improved adjusted EBITDA margin of approximately 11.5% to 12.5% for full year 2026, demonstrating sustainable profitability.
• Achieved free cash flow positivity for the first time in company history in 2025.
• Successfully completed a 12-month FDA remediation plan on time, indicating strong operational execution and quality systems.
• Presented real-world evidence from over 1.4 million patients reinforcing Zio long-term continuous monitoring (LTCM) clinical superiority.
• Submitted 510(k) for Zio MCT, a next-generation mobile cardiac telemetry device with extended 21-day wear and advanced algorithms, indicating product innovation.
• Signed a Lucem Health AI partnership to enable predictive identification of high-risk patients, enhancing future capabilities.
• Expanded commercial presence in six international markets and generated over 12 million patient reports worldwide to date.
• Zio is covered by incremental payer policies, expanding market access.

Risks

• Forward-looking statements are subject to various risks and uncertainties that could cause actual outcomes and results to differ materially.
• Risks include the effect of the announcement of the Holding Company Transaction on iRhythm Holdings' business generally, unexpected issues arising post-completion, and market reaction.
• The ability to realize the expected benefits of the Holding Company Transaction is not guaranteed.
• The company's ability to penetrate the market, achieve anticipated productivity and quality improvements, and sustain growth are subject to change based on various important factors beyond control.

Future Outlook

The company anticipates strong revenue growth of 17% to 18% year-over-year for fiscal year 2026, reaching $870 million to $880 million, with an adjusted EBITDA margin of 11.5% to 12.5%. Key growth catalysts include deepening penetration in primary care and population health through AI-powered risk stratification partnerships, continued momentum within mobile cardiac telemetry, expansion into adjacent markets such as obstructive sleep apnea, and sustained international execution. The company also plans to introduce next-generation Zio MCT and evolve its AI capabilities from detection towards prediction and insights generation.

Management Comments

• "2025 has been a transformative year for iRhythm, with strong execution against our aspiration to drive best-in-class quality systems, record commercial volumes, over 25% year-over-year revenue growth, and achieving free cash flow positivity for the first time in company history."
• "Our comprehensive clinical evidence program continues to reinforce Zio LTCM's clinical superiority in support of addressable market expansion across additional populations and care settings."
• "As we enter 2026, we're well-positioned to accelerate our leadership with multiple growth catalysts ahead, including deepening penetration in primary care and population health through AI-powered risk stratification partnerships, momentum within mobile cardiac telemetry, expansion into adjacent markets such as obstructive sleep apnea, and continued international execution."
• "With our proven ability to scale efficiently, we're confident we can deliver sustainable, profitable growth while transforming cardiac care for millions of patients worldwide."

Industry Context

The announcement positions iRhythm Holdings within a growing healthcare landscape characterized by an aging population, increasing consumer arrhythmia awareness, and a shift towards proactive and value-based care. The company is addressing a significant access gap, with nearly half of U.S. counties lacking cardiologists and long wait times for appointments. iRhythm's focus on AI-powered diagnostics, wearable biosensors, and cloud-based analytics aligns with broader digital health trends aimed at improving patient outcomes and healthcare efficiency. Expansion into areas like obstructive sleep apnea also reflects a strategy to leverage existing technology and market presence for adjacent, high-prevalence conditions.

Comparison to Industry Standards

• iRhythm holds a dominant 72% market share in the U.S. long-term continuous monitoring (LTCM) market, which is currently 3.5 million tests annually and growing at a high-teens percentage year-over-year, indicating strong leadership compared to competitors.
• The company's 15% market share in the U.S. mobile cardiac telemetry (MCT) market (1.1 million tests annually, growing high single-digit percentage year-over-year) suggests room for significant growth, with each 10 points of share representing an $80-$100 million revenue opportunity.
• The extensive clinical evidence program, including AVALON and CAMELOT publications and recent data presented at APHRS and AHA, reinforces Zio LTCM's clinical superiority, differentiating it from other ambulatory cardiac monitoring (ACM) modalities and supporting market expansion.
• The company's achievement of free cash flow positivity for the first time in its history in 2025, alongside anticipated adjusted EBITDA margin expansion to 11.5%-12.5% in 2026, demonstrates a strong financial performance trajectory compared to many growth-stage medical technology companies.
• The submission of a 510(k) for Zio MCT with extended 21-day wear and advanced algorithms indicates competitive innovation against other MCT providers like BioTelemetry (now Philips) and Preventice (now Boston Scientific).

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Existing shareholders of iRhythm Technologies, Inc. will automatically become shareholders of iRhythm Holdings, Inc. on a one-for-one basis, with the transaction intended to be tax-free for U.S. federal income tax purposes. The trading symbol and CUSIP remain unchanged, ensuring continuity and minimal disruption to their investment. The strong financial outlook and strategic growth initiatives are positive for shareholder value.
• **Employees**: The executive officers and directors remain the same, indicating stability in leadership. Equity compensation plans have been assumed by iRhythm Holdings, ensuring continuity of employee benefits and incentives.
• **Customers**: The company's focus on clinical superiority, product innovation (Zio MCT), and market expansion (primary care, population health, OSA) suggests continued and improved service offerings. EHR integrations aim to streamline clinician workflows.
• **Creditors**: Holders of Convertible Senior Notes will have their conversion rights adjusted to iRhythm Holdings Common Stock, and iRhythm Holdings will fully and unconditionally guarantee the obligations, maintaining or enhancing the security of their investment.

Next Steps

• iRhythm Technologies, Inc. will file a Form 15 with the SEC to deregister its common stock and suspend reporting obligations.
• iRhythm Holdings, Inc. will become the successor issuer and will make all future SEC filings under the prior CIK.
• The Nasdaq marketplace will reflect the name change to iRhythm Holdings, Inc. on January 13, 2026.
• iRhythm Holdings expects the Holding Company Transaction to be reflected in The Depository Trust Company facilities on January 13, 2026.
• Continue deepening penetration in primary care and population health through AI-powered risk stratification partnerships.
• Advance momentum within mobile cardiac telemetry, including the potential FDA clearance and commercialization of the next-generation Zio MCT.
• Expand into adjacent markets such as obstructive sleep apnea.
• Continue international execution and market penetration in the UK, Japan, and prioritized EU countries.
• Further develop AI capabilities to evolve from detection towards prediction and insights generation in cardiac care.

Key Dates

Recommendation

The filing indicates a strong 'better than expected' performance with preliminary 2025 revenue exceeding guidance and an optimistic 2026 outlook projecting 17-18% growth and improved EBITDA margins. The company achieved free cash flow positivity for the first time, completed a critical FDA remediation plan on time, and is actively pursuing multiple growth catalysts including new product development (Zio MCT), AI partnerships, and international expansion. The corporate reorganization is a non-dilutive, tax-free event for shareholders, maintaining operational continuity. These factors collectively point to robust operational execution, strong financial momentum, and significant future growth potential, making it a compelling 'strong buy' for investors.

Keywords

iRhythm Holdings, IRTC, SEC filing, 8-K, corporate reorganization, holding company, financial outlook, revenue guidance, EBITDA margin, Zio LTCM, mobile cardiac telemetry, MCT, obstructive sleep apnea, AI, artificial intelligence, digital health, cardiac monitoring, clinical evidence, Nasdaq, convertible notes